Items Tagged ‘Arimidex’

January 20th, 2016

Quality of Life Helps Determine Type of Hormone Treatment in Early Breast Cancer

By

Quality of life issues and different side effects caused by treatment may help determine which type of hormone therapy is most appropriate for postmenopausal women with ductal carcinoma in situ, particularly among women 60 years of age or older. These results were recently published in The Lancet. Hormone-positive breast cancers, which comprise approximately 75% of […]

View full entry

Tags: anastrozole, Arimidex, Breast Cancer, Carcinoma In Situ Breast cancer, DCIS, News, tamoxifen


June 9th, 2015

Arimidex® More Effective than Tamoxifen in Prevention of Recurrence in Early Breast Cancer

By

For patients with a common type of breast cancer known as ductal carcinoma in situ (DCIS), the drug Arimidex® (anastrozole) may provide better protection against recurrence than tamoxifen. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical […]

View full entry

Tags: anastrozole, Arimidex, Breast Cancer, Carcinoma In Situ Breast cancer, DCIS, ductal carcinoma in situ, News, tamoxifen


March 9th, 2015

Study Suggests Faslodex® Could Become New Standard First-Line Treatment of Metastatic Breast Cancer

By

Faslodex® (fulvestrant) at a 500-mg dose has been demonstrated to be superior to Arimidex® (anastrozole) as first-line therapy for advanced hormone receptor–positive breast cancer in the phase II FIRST study.1 Both overall survival and time to cancer progression were significantly better with Faslodex® than with the current standard of care, Arimidex®. Each year roughly 200,000 U.S. […]

View full entry

Tags: advanced hormone receptor-positive, anastrozole, Arimidex, Breast Cancer, CONFIRM, estrogen receptor antagonist, Faslodex, fulvestrant, Metastatic Breast Cancer, News, Recurrent Breast Cancer